Related references
Note: Only part of the references are listed.Causality assessment of adverse drug reaction: A narrative review to find the most exhaustive and easy-to-use tool in post-authorization settings
Pallavi Pradhan et al.
JOURNAL OF APPLIED BIOMEDICINE (2023)
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms
Rhonda M. Cooper-DeHoff et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
Henrike Bruckmueller et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2021)
Common Statin Intolerance Variants in ABCB1 and LILRB5 Show Synergistic Effects on Statin Response: An Observational Study Using Electronic Health Records
Alaa' Lutfi Melhem et al.
FRONTIERS IN GENETICS (2021)
Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis
Qian Xiang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
A practical algorithm for the management of patients with statin-associated muscle symptoms
Loukianos S. Rallidis
HELLENIC JOURNAL OF CARDIOLOGY (2020)
Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia
Lisanne M. Geers et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins
Takeshi Hirota et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2020)
Pharmacogenetics of Statin-Induced Myotoxicity
Ping Siu Kee et al.
FRONTIERS IN GENETICS (2020)
Association of SLCO1B1 and ABCB1 Genetic Variants with Atorvastatin-induced Myopathy in Patients with Acute Ischemic Stroke
Limin Zhang et al.
CURRENT PHARMACEUTICAL DESIGN (2019)
Clinical features related to statin-associated muscle symptoms
Heather M. Ochs-Balcom et al.
MUSCLE & NERVE (2019)
The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition
Fen Jiang et al.
PHARMACOGENOMICS (2017)
Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?
Danina M. Muntean et al.
DRUG DISCOVERY TODAY (2017)
The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability
Robert S. Rosenson et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers
Rafael B. R. Leon-Cachon et al.
BMC CANCER (2016)
Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population
P. Kadam et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2016)
Statin-Associated Side Effects
Paul D. Thompson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes
Rocco C. Venuto et al.
MEDICINE (2015)
Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2
Marco Ferrari et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review
William J. Canestaro et al.
GENETICS IN MEDICINE (2014)
Resistance and intolerance to statins
Z. Reiner
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2014)
Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care
Marianne K. DeGorter et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2013)
Clinical response to statins: Mechanism(s) of variable activity and adverse effects
Cesare R. Sirtori et al.
ANNALS OF MEDICINE (2012)
CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are Determinants of Inter-subject Variability in Fluvastatin Pharmacokinetics in Healthy Chinese Volunteers
Q. Zhou et al.
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH (2012)
The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort
Michel R. Hoenig et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)
Laura M. Hodges et al.
PHARMACOGENETICS AND GENOMICS (2011)
Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy
Matthijs L. Becker et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2010)
ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy
Monica Hermann et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment
M Fiegenbaum et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Share Paper
